46 terminated. 46 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 46 | Terminated 46 |
Follow Hepatitis: new trials by email Literature Review of Hepatitis trials Research Report on Hepatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers Hepatitis B Vaccine (Recombinant) - Hepatitis B | Phase 4 | Terminated | Rockefeller University | 9 | 2022-12-10 | 2026-04-16 |
| HCV Test and Treat Utilizing Simplified HCV Patient Education Cepheid POC HCV Viremia (RNA) test, HCV education from a health care provider, Glecaprevir and Pibrentasvir - Hepatitis C | Phase 4 | Terminated | Weill Medical College of Cornell University | 8 | 2022-11-11 | 2025-02-27 |
| QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir Glecaprevir and Pibrentasvir - Kidney Failure, Hepatitis C | Phase 4 | Terminated | Massachusetts General Hospital | 2 | 2021-05-01 | 2024-12-03 |
| ATTIC - Access To Treat in the Community ZEPATIER 50Mg-100Mg Tablet - Hepatitis C, Chronic | Phase 4 | Terminated | King's College Hospital NHS Trust | 13 | 2019-03-23 | 2023-05-06 |
| Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation grazoprevir 100 mg/ elbasvir 50 mg, Zepatier® - Chronic Hepatitis c, Liver Transplant Infection | Phase 4 | Terminated | Taichung Veterans General Hospital | 14 | 2019-02-14 | 2021-03-16 |
| Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks - Respiratory Failure, Hepatitis C | Phase 4 | Terminated | Massachusetts General Hospital | 19 | 2019-02-05 | 2023-04-25 |
| The Dublin Zepatier Study Zepatier - Hepatitis C | Phase 4 | Terminated | Mater Misericordiae University Hospital | 3 | 2018-03-15 | 2019-12-10 |
| DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant Treatment with Direct Acting Antiviral tablet - End Stage Liver Disease, Hepatitis C | Phase 4 | Terminated | Massachusetts General Hospital | 33 | 2017-11-21 | 2022-07-28 |
| DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant Clinically prescribed direct acting antiviral - End Stage Heart Disease, Hepatitis C | Phase 4 | Terminated | Massachusetts General Hospital | 40 | 2017-11-09 | 2022-06-22 |
| MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV OBV/PTV/r and DSV, Placebo to match OBV/PTV/r and DSV - Hepatitis C, Chronic | Phase 4 | Terminated | Hannover Medical School | 5 | 2017-10-24 | 2023-08-14 |
| Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment Epclusa - Hepatitis C, Chronic, Lung Transplant | Phase 4 | Terminated | Duke University | 1 | 2017-09-15 | 2019-09-11 |
| Impact of Hepatitis C Therapy and Bone Health EBR/GZR - Human Immunodeficiency Virus, Hepatitis C | Phase 4 | Terminated | Dallas VA Medical Center | 6 | 2017-08-28 | 2019-08-19 |
| Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs Grazoprevir/elbasvir - Hepatitis C | Phase 4 | Terminated | Kirby Institute | 32 | 2017-05-01 | 2020-03-09 |
| Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study sofosbuvir/ledipasvir, sofosbuvir, Ribavirin - Liver Disease | Phase 4 | Terminated | University of Texas Southwestern Medical Center | 1 | 2016-02-25 | 2019-01-08 |
| Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection. Ribavirin - Hepatitis E | Phase 4 | Terminated | Hospital Universitari Vall d'Hebron Research Institute | 5 | 2015-12-01 | 2019-04-16 |
| Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection Tenofovir DF, DEXA Scan - Hepatitis B | Phase 4 | Terminated | Gilead Sciences | 30 | 2015-07-03 | 2019-05-20 |
| Effects of Persistent Innate Immune Activation on Vaccine Efficacy Recombivax - Hepatitis C Infection | Phase 4 | Terminated | Rockefeller University | 24 | 2015-05-08 | 2020-03-04 |
| Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C Vitamin D, Vitamin B 12 - RNA Virus Infections, Flaviviridae Infections | Phase 4 | Terminated | Federal University of São Paulo | 85 | 2014-03-01 | 2016-08-24 |
| Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059) PEG-IFN alfa-2b, ribavirin - Hepatitis C, Chronic | Phase 4 | Terminated | Merck Sharp & Dohme LLC | 45 | 2013-01-01 | 2018-10-25 |
| Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation Lamivudine, Entecavir - Chronic Hepatitis B | Phase 4 | Terminated | Taichung Veterans General Hospital | 17 | 2012-07-01 | 2016-10-18 |
Showing 20 of 46. Sign in to see all of them.
Hepatitis C (22) · Hepatitis C, Chronic (16) · Hepatitis B, Chronic (7) · Acquired Immunodeficiency Syndrome (3) · HIV Infections (3) · Hepatitis B (2) · Liver Cirrhosis (2) · Liver Diseases (2) · Anemia (1) · Depression (1) · End Stage Liver Disease (1) · Fatigue (1) · Fatty Liver (1) · Flaviviridae Infections (1) · Heart Diseases (1)
Digestive System Diseases (46) · Hepatitis, Viral, Human (45) · Infections (45) · Virus Diseases (45) · Blood-Borne Infections (44) · Communicable Diseases (44) · Liver Diseases (44) · RNA Virus Infections (35) · Flaviviridae Infections (34) · Pathological Conditions, Signs and Symptoms (27) · Pathologic Processes (26) · Chronic Disease (25) · Disease Attributes (25) · Hepatitis, Chronic (23)
Ribavirin (15) · peginterferon alfa-2b (7) · elbasvir-grazoprevir drug combination (5) · clevudine (4) · peginterferon alfa-2a (4) · Lamivudine (3) · glecaprevir and pibrentasvir (3) · Hepatitis B Vaccines (2) · Therapeutics (2) · adefovir (2) · entecavir (2) · sofosbuvir-velpatasvir drug combination (2) · telaprevir (2) · Absorptiometry, Photon (1) · Buprenorphine (1)
Merck Sharp & Dohme LLC (5) · Massachusetts General Hospital (4) · Bukwang Pharmaceutical (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Rockefeller University (2) · Taichung Veterans General Hospital (2) · Weill Medical College of Cornell University (2) · Dallas VA Medical Center (1) · Duke University (1) · Federal University of São Paulo (1) · Gilead Sciences (1) · Göteborg University (1) · Hannover Medical School (1) · Haukeland University Hospital (1) · HepNet Study House, German Liverfoundation (1)
United States (19) · South Korea (5) · Germany (3) · Taiwan (3) · Spain (2) · Switzerland (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Brazil (1) · France (1) · Greece (1) · Ireland (1) · Italy (1) · Norway (1)
Adauto Castelo, PhD (1) · Andrew Talal, MD (1) · Charles Rice, PhD (1) · Chen-Hua Liu, MD (1) · Cheng-Chao Liang, MD, BS (1) · Chi-Yi Chen, M.D. (1) · Chih-Lin Lin, MD, BS (1) · Christian Trautwein, Professor MD (1) · Chun-Che Lin, M.D. (1) · Colleen M Hadigan, M.D. (1) · Gabriel D. Victora, PhD (1) · Greg Dore, MBBS (1) · Gunnar PE Norkrans, MD Prof (1)
PMID 21876446, PMID 23795661, PMID 25909356, PMID 26057627, PMID 27720838, PMID 28193518, PMID 28539950, PMID 28671553, PMID 31353243, PMID 32270056, PMID 34902265
2014 (1), 2015 (1), U19AI111825 (1)